Literature DB >> 1233209

Persistent parotid pain due to guanacline.

M Parker.   

Abstract

Details are given of 17 patients who developed parotid pain during treatment with guanacline and which persisted after cessation of guanacline for upto five and a half years. These patients are compared with 17 patients who received similar treatment with guanacline and who did not develop parotid pain. There was no significant difference between patients who experienced parotid pain and those who did not with respect to sex, age, clinical diagnosis, blood urea, previous hypotensive therapy or other drugs given concurrently with guanacline. There was a slightly greater association of parotid pain with other side effects and with a larger daily dose of guanacline. It is suggested that persistent parotid pain after guanacline therapy is due to prolonged or permanent selective sympathetic nerve damage in the region of the cervical sympathetic nerve supply to the salivary glands.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233209     DOI: 10.1007/bf00561562

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Supersensitivity of salivary glands following treatment with bretylium or guanethidine.

Authors:  N EMMELIN; J ENGSTROM
Journal:  Br J Pharmacol Chemother       Date:  1961-06

2.  Clinical experience with guanacline, a new antihypertensive agent.

Authors:  G V Hall; G Michell
Journal:  Med J Aust       Date:  1968-06-15       Impact factor: 7.738

3.  A comparison of guanacline with methyldopa in the treatment of hypertension.

Authors:  G Jerums; A Ebringer; A E Doyle
Journal:  Med J Aust       Date:  1968-09-14       Impact factor: 7.738

4.  Prolonged hypotension and ultrastructural changes in sympathetic neurones following guanacline treatment.

Authors:  G Burnstock; A E Doyle; B J Gannon; J F Gerkens; T Iwayama; M L Mashford
Journal:  Eur J Pharmacol       Date:  1971-01       Impact factor: 4.432

5.  Guanacline, a new hypotensive drug.

Authors:  M Le Moine Parker; M Bullen
Journal:  Med J Aust       Date:  1969-01-25       Impact factor: 7.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.